Ziphius is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform. This platform enables higher and prolonged protein/antigen expression at lower doses (compared to conventional mRNA) with reduced toxicity. It also offers a ‘plug and play’ approach, facilitating rapid development, scale-up, and production. These attributes make it well-suited as a platform to enhance pandemic preparedness. Our strategic developments focus on infectious and rare diseases, as well as oncology.